The "Expert Consensus on Off-label Use of Bevacizumab" discusses the role of angiogenesis in tumor growth and the drug's efficacy beyond its initial approval for advanced non-small cell lung cancer. It provides evidence-based recommendations for off-label uses in various cancers and retinal diseases, including metastatic colorectal cancer and diabetic macular edema. The consensus highlights the need for informed consent and institutional approval for off-label use, as well as the management of potential adverse reactions, aiming to guide clinical practice in expanding bevacizumab's therapeutic applications.